Lowest Price Guaranteed
Slides
187
Last Updated
August 2026
View Count
5454
1. PREFACE
1.1. Introduction
1.2. Report Coverage
1.3. Market Segmentation
1.4. Key Market Insights
1.5. Market Share Insights
1.6. Key Questions Answered
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control
3. MARKET DYNAMICS
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations
4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross Border Dynamics
4.3. Conclusion
5. EXECUTIVE SUMMARY
6. INTRODUCTION
6.1. Chapter Overview
6.2. Evolution of AI
6.3. Subfields of AI
6.4. Applications of AI in Healthcare
6.4.1. Drug Discovery
6.4.2. Drug Manufacturing
6.4.3. Marketing
6.4.4. Diagnosis and Treatment
6.4.5. Clinical Trials
6.5. AI in Clinical Trials
6.6. Challenges Associated with the Adoption of AI
6.7. Future Perspective
7. MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Asia-Pacific AI in Clinical Trials Market: AI Software and Service Providers Landscape
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Analysis by Location of Headquarters
7.2.4. Analysis by Company Size and Location of Headquarters (Region)
7.2.5. Analysis by Key Offerings
7.2.6. Analysis by Deployment Options
7.2.7. Analysis by Type of AI Technology Used
7.2.8. Analysis by End-user
7.2.9. Analysis by Application Area
8. COMPANY PROFILES
8.1. Chapter Overview
8.2. HealthMatch*
8.2.1. Company Overview
8.2.2. AI in Clinical Trials Software and Services Portfolio
8.2.3. Recent Developments and Future Outlook
* Similar details are presented for other companies mentioned below (based on information in the public domain)
8.3. Lunit
8.4. Medidata Solutions
8.5. Oncoshot
8.6. Pathkey.AI
8.7. Taimei Technology
9. CLINICAL TRIAL ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Asia-Pacific AI in Clinical Trials Market
9.3.1. Analysis by Trial Registration Year
9.3.2. Analysis by Number of Patients Enrolled
9.3.3. Analysis by Trial Phase
9.3.4. Analysis by Trial Status
9.3.5. Analysis by Trial Registration Year and Status
9.3.6. Analysis by Type of Sponsor
9.3.7. Analysis by Patient Gender
9.3.8. Analysis by Patient Age
9.3.9. Word Cloud Analysis: Emerging Focus Areas
9.3.10. Analysis by Target Therapeutic Area
9.3.11. Analysis by Study Design
9.3.11.1. Analysis by Type of Patient Allocation Model Used
9.3.11.2. Analysis by Type of Trial Masking Adopted
9.3.11.3. Analysis by Type of Intervention
9.3.11.4. Analysis by Trial Purpose
9.3.12. Most Active Players: Analysis by Number of Clinical Trials
10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Asia-Pacific AI in Clinical Trials Market: Partnerships and Collaborations
10.3.1. Analysis by Monthly Trend of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Type of Partner
10.3.4. Most Active Players: Analysis by Number of Partnerships
11. FUNDING AND INVESTMENT ANALYSIS
11.1. Chapter Overview
11.2. Funding Models
11.3. Asia-Pacific AI in Clinical Trials Market: Funding and Investments
11.3.1. Analysis of Instances by Month-Year of Funding
11.3.2. Analysis of Amount Invested by Month-Year of Funding
11.3.3. Analysis of Instances by Type of Funding
11.3.4. Analysis of Amount Invested by Type of Funding
11.3.5. Most Active Players: Analysis by Number of Funding Instances
11.3.6. Leading Investors: Analysis by Number of Funding Instances
11.4. Concluding Remarks
12. BIG PHARMA INITIATIVES
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Analysis by Year of Initiative
12.4. Analysis by Type of Initiative
12.5. Analysis by Application Area of AI
12.6. Analysis by Target Therapeutic Area
12.7. Benchmarking Analysis: Big Pharma Players
13. VALUE CREATION FRAMEWORK: A STRATEGIC GUIDE TO ADDRESS UNMET NEEDS IN CLINICAL TRIALS
13.1. Chapter Overview
13.2. Unmet Needs in Clinical Trials
13.3. Key Assumptions and Methodology
13.4. Key Tools and Technologies
13.4.1. Blockchain
13.4.2. Big Data Analytics
13.4.3. Real-world Evidence
13.4.4. Digital Twins
13.4.5. Cloud Computing
13.4.6. Internet of Things (IoT)
13.5. Trends in Research Activity
13.6. Trends in Intellectual Capital
13.7. Extent of Innovation versus Associated Risks
13.8. Results and Discussion
14. COST SAVING ANALYSIS
14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. Overall Cost Saving Potential from AI Adoption in Asia-Pacific Registered Clinical Trials, Till 2035
14.3.1. Cost Saving Potential: Distribution by Trial Phase, Till 2035
14.3.1.1. Cost Saving Potential in Phase I Clinical Trials, Till 2035
14.3.1.2. Cost Saving Potential in Phase II Clinical Trials, Till 2035
14.3.1.3. Cost Saving Potential in Phase III Clinical Trials, Till 2035
14.3.2. Cost Saving Potential: Distribution by Trial Procedure, Till 2035
14.3.2.1. Cost Saving Potential in Patient Recruitment, Till 2035
14.3.2.2. Cost Saving Potential in Staffing and Administration, Till 2035
14.3.2.3. Cost Saving Potential in Site Monitoring, Till 2035
14.3.2.4. Cost Saving Potential in Source Data Verification, Till 2035
14.3.2.5. Cost Saving Potential in Patient Retention, Till 2035
14.3.2.6. Cost Saving Potential in Other Procedures, Till 2035
14.4. Conclusion
15. MARKET IMPACT ANALYSIS
15.1. Chapter Overview
15.2. Market Drivers
15.3. Market Restraints
15.4. Market Opportunities
15.5. Market Challenges
15.6. Conclusion
16. ASIA-PACIFIC AI IN CLINICAL TRIALS MARKET
16.1. Chapter Overview
16.2. Assumptions and Methodology
16.3. Roots Analysis Perspective on Market Growth
16.4. Asia-Pacific AI in Clinical Trials Market: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
16.4.1. Scenario Analysis
16.4.1.1. Conservative Scenario
16.4.1.2. Optimistic Scenario
16.5. Key Market Segmentation
17. ASIA-PACIFIC AI IN CLINICAL TRIALS MARKET, BY TRIAL PHASE
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Asia-Pacific AI in Clinical Trials Market: Distribution by Trial Phase
17.3.1. Asia-Pacific AI in Clinical Trials Market for Phase I: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
17.3.2. Asia-Pacific AI in Clinical Trials Market for Phase II: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
17.3.3. Asia-Pacific AI in Clinical Trials Market for Phase III: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
17.4. Data Triangulation and Validation
18. ASIA-PACIFIC AI IN CLINICAL TRIALS MARKET, BY TYPE OF OFFERING
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Asia-Pacific AI in Clinical Trials Market: Distribution by Type of Offering
18.3.1. Asia-Pacific AI in Clinical Trials Market for Software: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
18.3.2. Asia-Pacific AI in Clinical Trials Market for Services: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
18.4. Data Triangulation and Validation
19. ASIA-PACIFIC AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Asia-Pacific AI in Clinical Trials Market: Distribution by Deployment Mode
19.3.1. Asia-Pacific AI in Clinical Trials Market for Cloud-based Deployment: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
19.3.2. Asia-Pacific AI in Clinical Trials Market for On-premises Deployment: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
19.4. Data Triangulation and Validation
20. ASIA-PACIFIC AI IN CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Asia-Pacific AI in Clinical Trials Market: Distribution by Therapeutic Area
20.3.1. Asia-Pacific AI in Clinical Trials Market for Oncological Disorders: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
20.3.2. Asia-Pacific AI in Clinical Trials Market for Infectious Diseases: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
20.3.3. Asia-Pacific AI in Clinical Trials Market for CNS Disorders: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
20.3.4. Asia-Pacific AI in Clinical Trials Market for Metabolic Disorders: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
20.3.5. Asia-Pacific AI in Clinical Trials Market for Immunological Disorders: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
20.3.6. Asia-Pacific AI in Clinical Trials Market for Cardiovascular Disorders: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
20.3.7. Asia-Pacific AI in Clinical Trials Market for Other Disorders: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
20.4. Data Triangulation and Validation
21. ASIA-PACIFIC AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY EXPOSURE
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Asia-Pacific AI in Clinical Trials Market: Distribution by Technology Exposure
21.3.1. Asia-Pacific AI in Clinical Trials Market for Machine Learning: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
21.3.2. Asia-Pacific AI in Clinical Trials Market for Molecular Modeling and Simulation: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
21.3.3. Asia-Pacific AI in Clinical Trials Market for Deep Learning: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
21.3.4. Asia-Pacific AI in Clinical Trials Market for Omics Integration: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
21.3.5. Asia-Pacific AI in Clinical Trials Market for Generative Models: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
21.3.6. Asia-Pacific AI in Clinical Trials Market for Other Technologies: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
21.4. Data Triangulation and Validation
22. ASIA-PACIFIC AI IN CLINICAL TRIALS MARKET, BY END-USER
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Asia-Pacific AI in Clinical Trials Market: Distribution by End-user
22.3.1. Asia-Pacific AI in Clinical Trials Market for Biotechnology and Pharmaceutical Companies: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
22.3.2. Asia-Pacific AI in Clinical Trials Market for Academic Research Institutes and Other End-users: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
22.3.3. Asia-Pacific AI in Clinical Trials Market for Other End-users: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
22.4. Data Triangulation and Validation
23. ASIA-PACIFIC AI IN CLINICAL TRIALS MARKET, BY COUNTRIES
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Asia-Pacific AI in Clinical Trials Market: Distribution by Countries
23.3.1. Asia-Pacific AI in Clinical Trials Market in China: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
23.3.2. Asia-Pacific AI in Clinical Trials Market in Japan: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
23.3.3. Asia-Pacific AI in Clinical Trials Market in South Korea: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
23.3.4. Asia-Pacific AI in Clinical Trials Market in Australia: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
23.3.5. Asia-Pacific AI in Clinical Trials Market in India: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
23.3.6. Asia-Pacific AI in Clinical Trials Market in Rest of Asia-Pacific: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
23.4. Data Triangulation and Validation
24. CONCLUSION
25. EXECUTIVE INSIGHTS
25.1. Chapter Overview
25.2. Company A
25.2.1. Company Snapshot
25.2.2. Interview Transcript: Co-Founder, Chief Executive Officer and Chief Technology Officer
25.3. Company B
25.3.1. Company Snapshot
25.3.2. Interview Transcript: Founder and Chief Executive Officer
25.4. Company C
25.4.1. Company Snapshot
25.4.2. Interview Transcript: Co-Founder and Executive Director
25.5. Company D
25.5.1. Company Snapshot
25.5.2. Interview Transcript: Founder and Chief Executive Officer
25.6. Company E
25.6.1. Company Snapshot
25.6.2. Interview Transcript: Chief Technology Officer, Chief Commercial Officer, Chief Delivery Officer, Head of Marketing
25.7. Company F
25.7.1. Company Overview
25.7.2. Interview Transcript: Chief Science Officer, Co-Founder, Chief Executive Officer, Chief Executive Officer and Associate Professor and Blue Cross California Distinguished Professor
25.8. Company G
25.8.1. Company Overview
25.8.2. Interview Transcript: EVP, Chief Information, Technology, and Product Officer
25.9. Company H
25.9.1. Company Overview
25.9.2. Interview Transcript: Co-Founder and Chief Executive Officer
25.10. Company I
25.10.1. Company Overview
25.10.2. Interview Transcript: Chief Technology Officer
25.11. Company J
25.11.1. Company Overview
25.11.2. Interview Transcript: Director of the Office of Medical Policy (CDER)
25.12. Company K
25.12.1. Company Overview
25.12.2. Interview Transcript: Professor of Medicine; Program Manager; Director, Bioethics Lead; Associate Dean, Human Research Protections and Director of the Human Research Protections Program; Executive IRB Chair and VP of IBC Affairs
25.13. Company L
25.13.1. Company Overview
25.13.2. Interview Transcript: Hematologist, AI Specialist, and Research Group Leader
25.14. Company M
25.14.1. Company Overview
25.14.2. Interview Transcript: Cardiologist and Associate Director of the Accelerator for Clinical Transformation Research Group
25.15. Company N
25.15.1. Company Overview
25.15.2. Interview Transcript: Heart Failure Cardiologist and Researcher
25.16. Company O
25.16.1. Company Overview
25.16.2. Interview Transcript: Senior Community Development Manager
26. APPENDIX I: TABULATED DATA
27. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS